Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
08:00am, Wednesday, 23'rd Oct 2024
Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J. , Oct. 23, 2024 /PRNewswire/ -- Insmed I
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 17'th Oct 2024
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
08:00am, Thursday, 17'th Oct 2024
BRIDGEWATER, N.J. , Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J. , Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to d
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 04'th Oct 2024
BRIDGEWATER, N.J. , Oct. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
These 12 Stocks are Ripe for a Short Squeeze
10:51am, Tuesday, 10'th Sep 2024
Subscribers to Chart of the Week received this commentary on Sunday, September 8.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Sep 2024
BRIDGEWATER, N.J. , Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach
05:31pm, Wednesday, 28'th Aug 2024
Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025, pend
Insmed Stock Surges 168% in the Past Six Months: Here's Why
12:10pm, Tuesday, 27'th Aug 2024
Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
Meta Stock Leads 5 Names Near Buy Points As Market Bounces
08:00am, Saturday, 24'th Aug 2024
Meta leads five stocks near buy points as the market rallied Friday on Fed Chair Jerome Powell's speech.
Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript
04:11pm, Friday, 09'th Aug 2024
Insmed Incorporated (NASDAQ:INSM ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Bryan Dunn – Head-Investor Relations Will Lewis – Chair and Chief Executive Offic
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
12:47pm, Friday, 09'th Aug 2024
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics
10:35am, Thursday, 08'th Aug 2024
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street es
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
09:10am, Thursday, 08'th Aug 2024
Insmed (INSM) came out with a quarterly loss of $1.94 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.78 per share a year ago.
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
07:00am, Thursday, 08'th Aug 2024
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness
